Investors declined to reward NxStage Medical (NSDQ:NXTM) today for another in a string of solid quarters, sending share prices down YY% despite higher sales, narrowed losses and re-affirmed guidance.
MassDevice Earnings Roundup
Weak Rio sales gut Mako Surgical
Shares of Mako Surgical (NSDQ:MAKO) are down nearly 36% today, their lowest mark in 4 months, after the robotic surgery company missed its own 1st-quarter guidance.
The Ft. Lauderdale-based company reported losses of $11.7 million, or 28¢ per share, on sales of $19.6 million for the 3 months ended March 31, representing top-line growth of 50.8% but a bottom-line slide of 6.7%
CareFusion hits 52-week high on Q3 results | Earnings Roundup
CareFusion (NYSE:CFN) hit a 52-week high Friday after beating Wall Street boffins’ predictions for its 3rd-quarter earnings and raising its full-year revenue guidance.
The San Diego-based medical device maker reported profits of $31 million, or 13¢ per diluted share, on sales of $919 million during the 3 months ended March 31, a top-line gain of 9.1%.
Sitting pretty: Even in recession-ravaged countries in Southern Europe, beauty sells | Earnings Roundup
Despite a crippling recession which puts it in the epicenter of the European debt crisis, it still seems Southern Europe puts a premium on not just the beauty of its land, but those of its people as well.
On Wednesday Allergan (NYSE:AGN) reported stronger than expected sales of its breast implants, Botox and other aesthetic devices in places like Spain, where the unemployment rate tips 24% – more than 3 times that of the U.S.
Volcano kills it in Japan, gains Street cred
Volcano’s (NSDQ:VOLC) Q1 earnings came in just shy of Wall Street analysts’ expectations as operating costs kept pace with a robust uptick in revenues.
Revenues during the 3 months ended March 31 grew 11.6% to $90.4 million, compared with $81 million during the same period last year, driven by some big boosts in regional sales.
AtriCure soars on Street-beating Q1 results
AtriCure (NSDQ:ATRC) shares gained nearly 15% this morning after it reported lower-than-expected losses and record revenues of $17.5 million for the 1st quarter.
The West Chester, Ohio-based atrial fibrillation device maker reported losses of $1.6 million, or 10¢ per share, on sales of $17.5 million for the 3 months ended March 31, representing an 11.8% top-line increase.
Smith & Nephew gains on Q1 results
Shares of Smith & Nephew (FTSE:SN, NYSE:SNN) are up nearly 4% today after the British health products giant posted sales and earnings increases for the 1sst quarter.
Masimo misses Q1 forecast on discounted Covidien royalties
Kensey Nash agrees to $360M buyout by Royal DSM
Kensey Nash (NSDQ:KNSY) agreed to a $38.50-per-share cash buyout offer from Royal DSM worth about $360 million, a 33% premium over KNSY’s $29.01 closing price yesterday.
KNSY shares soared 32.2% in pre-market trading on the news, reaching $38.35 – 25.7% above its 52-week high of $30.50 per share, even as the company revealed a 3rd-quarter swing from red ink to black.
Thoratec kills it in Q1, Wall Street shrugs | Earnings Roundup
Thoratec (NSDQ:THOR) started today up 7.2% as investors reacted to its stellar 1st-quarter numbers, but by the time the market closed THOR shares had fallen back to Earth to close at $34.46, down 0.1%.
The heart pump maker posted profits of $25.5 million, or 43¢ per diluted share, on sales of $126.8 million for the 3 months ended March 31.
Thoratec kills it in Q1, Wall Street shrugs
Thoratec (NSDQ:THOR) started today up 7.2% as investors reacted to its stellar 1st-quarter numbers, but by the time the market closed THOR shares had fallen back to Earth to close at $34.46, down 0.1%.
The heart pump maker posted profits of $25.5 million, or 43¢ per diluted share, on sales of $126.8 million for the 3 months ended March 31.